Unichem Laboratories Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Unichem LaboratoriesDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -36.9% zurückgegangen, während in der Branche Pharmaceuticals die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 5.6% pro Jahr.

Wichtige Informationen

-36.9%

Wachstumsrate der Gewinne

-36.8%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	17.5%
Wachstumsrate der Einnahmen	5.6%
Eigenkapitalrendite	-3.0%
Netto-Marge	-4.1%
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Feb 06

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Jul 23

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 15

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Jul 01

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Nov 27

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Jun 05

Should Unichem Laboratories Limited (NSE:UNICHEMLAB) Be Part Of Your Income Portfolio?

Mar 02

Unichem Laboratories Limited's (NSE:UNICHEMLAB) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?

Feb 09

Should You Take Comfort From Insider Transactions At Unichem Laboratories Limited (NSE:UNICHEMLAB)?

Jan 19

Do Institutions Own Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares?

Dec 29

Is Unichem Laboratories (NSE:UNICHEMLAB) Weighed On By Its Debt Load?

Dec 10

Key Things To Understand About Unichem Laboratories' (NSE:UNICHEMLAB) CEO Pay Cheque

Nov 23

Did Unichem Laboratories' (NSE:UNICHEMLAB) Share Price Deserve to Gain 41%?

Nov 02

Should You Buy Unichem Laboratories Limited (NSE:UNICHEMLAB) For Its 1.5% Dividend?

Oct 13

How Much Are Unichem Laboratories Limited (NSE:UNICHEMLAB) Insiders Spending On Buying Shares?

Sep 16

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Too Much Debt?

Aug 26

Is Unichem Laboratories Limited's (NSE:UNICHEMLAB) Shareholder Ownership Skewed Towards Insiders?

Aug 05

Would Shareholders Who Purchased Unichem Laboratories'(NSE:UNICHEMLAB) Stock Three Years Be Happy With The Share price Today?

Jul 14

Aufschlüsselung der Einnahmen und Ausgaben

Wie Unichem Laboratories Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NSEI:UNICHEMLAB Einnahmen, Ausgaben und Erträge (INR Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	17,049	-705	4,100	0
31 Dec 23	16,753	146	3,950	0
30 Sep 23	15,434	-1,333	3,874	0
30 Jun 23	14,566	-1,795	3,675	0
31 Mar 23	13,430	-2,022	3,690	0
31 Dec 22	13,109	-865	3,696	0
30 Sep 22	13,197	-367	3,614	0
30 Jun 22	12,815	212	3,530	0
31 Mar 22	12,698	331	3,468	0
31 Dec 21	11,740	-388	3,253	0
30 Sep 21	11,890	-12	3,211	0
30 Jun 21	12,158	204	3,152	0
31 Mar 21	12,351	343	3,113	0
31 Dec 20	13,581	175	3,112	0
30 Sep 20	13,067	-206	2,989	0
30 Jun 20	12,547	-516	2,916	0
31 Mar 20	11,037	-602	2,786	0
31 Dec 19	12,653	-113	2,745	0
30 Sep 19	12,711	51	2,697	0
30 Jun 19	12,366	-113	2,567	0
31 Mar 19	11,800	-256	2,475	0
31 Dec 18	10,425	-591	2,319	0
31 Mar 18	8,146	-1,331	2,090	0
31 Dec 17	15,855	405	4,258	585
31 Mar 17	6,977	-707	1,806	0
31 Mar 16	13,327	1,081	3,311	416
31 Mar 15	12,018	754	3,004	446
31 Mar 14	11,334	1,282	4,380	505

Qualität der Erträge: UNICHEMLAB ist derzeit unrentabel.

Wachsende Gewinnspanne: UNICHEMLAB ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: UNICHEMLAB ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 36.9% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von UNICHEMLAB verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: UNICHEMLAB ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (18%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: UNICHEMLAB hat eine negative Eigenkapitalrendite (-2.98%), da es derzeit unrentabel ist.

Unichem Laboratories Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Recent updates

High number of new directors

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

New major risk - Revenue and earnings growth

Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Optimistic Investors Push Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares Up 26% But Growth Is Lacking

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Is Unichem Laboratories (NSE:UNICHEMLAB) Using Debt Sensibly?

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Does Unichem Laboratories (NSE:UNICHEMLAB) Have A Healthy Balance Sheet?

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Unichem Laboratories (NSE:UNICHEMLAB) Is Due To Pay A Dividend Of ₹4.00

Upcoming dividend of ₹4.00 per share

There's Reason For Concern Over Unichem Laboratories Limited's (NSE:UNICHEMLAB) Massive 28% Price Jump

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories (NSE:UNICHEMLAB) Will Pay A Dividend Of ₹4.00

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories (NSE:UNICHEMLAB) Is Making Moderate Use Of Debt

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Investors Shouldn't Be Too Comfortable With Unichem Laboratories' (NSE:UNICHEMLAB) Robust Earnings

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration

Should Unichem Laboratories Limited (NSE:UNICHEMLAB) Be Part Of Your Income Portfolio?

New 90-day high: ₹332

Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited's (NSE:UNICHEMLAB) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Correct Its Share Price?

New 90-day high: ₹295

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020)

Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA

Unichem Laboratories Limited to Report Q3, 2021 Results on Jan 30, 2021

Should You Take Comfort From Insider Transactions At Unichem Laboratories Limited (NSE:UNICHEMLAB)?

New 90-day high: ₹286

Unichem Laboratories Limited Receives ANDA Approval from USFDA for Unichem's Celecoxib Capsules, 50 Mg, 100 Mg, 200 Mg, and 400 Mg

Do Institutions Own Unichem Laboratories Limited (NSE:UNICHEMLAB) Shares?